Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799761 | 0.88 | CRHR1 (0.37) | SMN1; SMN2LMNACYP1A2CYP2C19CYP3A4 | |
| SCHEMBL5845617 | 0.84 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL5845635 | 0.81 | CRHR1 (0.39) | SMN1; SMN2CRHR1MAPK1 | |
| SCHEMBL6802304 | 0.80 | CRHR1 (0.38) | CYP1A2CYP2C19CYP3A4CYP2C9CRHR1 | |
| SCHEMBL6798630 | 0.80 | CRHR1 (0.35) | CRHR1 | |
| SCHEMBL6796453 | 0.78 | CRHR1 (0.35) | CRHR1 | |
| SCHEMBL6799676 | 0.78 | POLB (0.45) | SMN1; SMN2LMNACYP1A2CYP2C19CYP3A4 | |
| SCHEMBL5846012 | 0.76 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL6798257 | 0.74 | MEN1 (0.36) | SMN1; SMN2CYP1A2CYP2C19CYP3A4CRHR1 | |
| SCHEMBL6797947 | 0.74 | CRHR1 (0.37) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833378-B2 | Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders. | PFIZER INC | 2004-12-21 | — | — | US | disclosed |
| US-20020016328-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016328-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | SMN1; SMN2 1860/4885LMNA 4189/4885CYP1A2 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.